Download PDF
CC BY-NC-ND 4.0 · AJP Rep 2020; 10(01): e101-e105
DOI: 10.1055/s-0040-1708492
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

How Reliable Is a Statewide Prescription Monitoring Program for Identifying Post-Cesarean Opioid Use?

Ashish Premkumar 
1   Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
,
Sedona E. Speedy
1   Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
,
Emily S. Miller
1   Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
› Author Affiliations Funding Funding for this study was provided by the National Institutes of Health's National Center for Advancing Translational Sciences grant (grant no.: UL1TR001422).
Further Information

Publication History

01 January 2020

24 January 2020

Publication Date:
19 March 2020 (online)

   Permissions and Reprints

Abstract

Objective This study was aimed to estimate the percentage of women taking opioids post-cesarean who could be detected in a state prescription monitoring program (PMP) and characteristics of those not able to be detected.

Study Design This observational cohort study included all women with an Illinois address who delivered via cesarean section and used opioids within 24 hours prior to discharge at a tertiary care hospital between August 21, 2017 and March 1, 2018. The Illinois PMP was queried for presence of an opioid prescription filled within the first 3 months postpartum. Sociodemographic and clinical factors associated with an undetectable PMP record were evaluated in bivariable and multivariable logistic regression analyses.

Results A total of 517 women underwent a cesarean delivery during the study period, of whom 344 (66.5%) met inclusion criteria. Of these women, 169 (49%) did not have a detectable PMP record of filling any outpatient postpartum prescription opioid. On bivariable and multivariable logistic regression analysis, year of delivery (2018 vs. 2017) was significantly associated with a higher incidence of detectable postpartum prescription opioid record in the PMP with increasing relative risk of detectable records in the second year of analyses (n = 110/244 [45%] in 2017 vs. n = 59/100 [59%] in 2018, adjusted risk ratio [aRR] = 1.32, 95% confidence interval [CI]: 1.06–1.64, p = 0.013). No other sociodemographic or clinical characteristics was significantly associated.

Conclusion Nearly half of women who underwent a cesarean section and who were administered opioids 24 hours prior to discharge did not have a detectable postpartum opioid prescription in the PMP. While identification of prescription filling improved with time, many of women were not detectable in the PMP system. These data call into question the accuracy of PMPs in identifying prescription opioid filling patterns in the postpartum setting.

Keywords

cesarean section - postpartum - opioid use - prescription monitoring program

Presentation

Accepted as an abstract at the Society for Maternal-Fetal Medicine's 40th Annual Pregnancy Meeting, February 3 to 8, 2020, Grapevine, Texas.


Supplementary Material

 

  • References

  • 1 President's Commission on Combating Drug Addiction and the Opioid Crisis. Roster of Commissioners. Available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/images/Final_Report_Draft_11-15-2017.pdf . Accessed February 12, 2020
    PubMed
  • 2 Ailes EC, Dawson AL, Lind JN. , et al; Centers for Disease Control and Prevention (CDC). Opioid prescription claims among women of reproductive age--United States, 2008-2012. MMWR Morb Mortal Wkly Rep 2015; 64 (02) 37-41
    PubMedGoogle Scholar
  • 3 Lankenau SE, Teti M, Silva K, Jackson Bloom J, Harocopos A, Treese M. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy 2012; 23 (01) 37-44
    CrossrefPubMedGoogle Scholar
  • 4 Jones CM. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers - United States, 2002-2004 and 2008-2010. Drug Alcohol Depend 2013; 132 (1,2): 95-100
    CrossrefPubMedGoogle Scholar
  • 5 Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014; 71 (07) 821-826
    CrossrefPubMedGoogle Scholar
  • 6 Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med 2016; 374 (02) 154-163
    CrossrefPubMedGoogle Scholar
  • 7 Committee on Obstetric Practice. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017; 130 (02) e81-e94
    CrossrefPubMedGoogle Scholar
  • 8 Sacco LN, Duff JH, Sarata AK. ; Congressional Research Services. Prescription Drug Monitoring Programs. Available at: https://fas.org/sgp/crs/misc/R42593.pdf . Accessed February 12, 2020
    PubMed
  • 9 Haffajee RL. Prescription drug monitoring programs - friend or folly in addressing the opioid-overdose crisis?. N Engl J Med 2019; 381 (08) 699-701
    CrossrefPubMedGoogle Scholar
  • 10 Amendment to Senate Bill 772. 2017. Available at https://www.ilpmp.org/PDF/Newlaw.pdf . Accessed January 1, 2020
    PubMed
  • 11 Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol 2014; 123 (05) 997-1002
    Google Scholar
  • 12 Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 national survey on drug use and health. Ann Intern Med 2017; 167 (05) 293-301
    CrossrefPubMedGoogle Scholar
  • 13 Peahl AF, Dalton VK, Montgomery JR, Lai YL, Hu HM, Waljee JF. Rates of new persistent opioid use after vaginal or cesarean birth among US women. JAMA Netw Open 2019; 2 (07) e197863
    CrossrefPubMedGoogle Scholar
  • 14 Reddy UM, Davis JM, Ren Z, Greene MF. ; Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes Workshop Invited Speakers. Opioid use in pregnancy, neonatal abstinence syndrome, and childhood outcomes: executive summary of a joint workshop by the eunice kennedy shriver national institute of child health and human development, American College Of Obstetricians And Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol 2017; 130 (01) 10-28
    CrossrefPubMedGoogle Scholar
  • 15 Vandenbroucke JP, von Elm E, Altman DG. , et al; STROBE Initiative. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4 (10) e297
    CrossrefPubMedGoogle Scholar
  • 16 Prabhu M, Dubois H, James K. , et al. Implementation of a quality improvement initiative to decrease opioid prescribing after cesarean delivery. Obstet Gynecol 2018; 132 (03) 631-636
    CrossrefPubMedGoogle Scholar
  • 17 Wilson MN, Hayden JA, Rhodes E, Robinson A, Asbridge M. Effectiveness of prescription monitoring programs in reducing opioid prescribing, dispensing, and use outcomes: a systematic review. J Pain 2019; 20 (12) 1383-1393
    CrossrefPubMedGoogle Scholar
  • 18 Osmundson SS, Schornack LA, Grasch JL, Zuckerwise LC, Young JL, Richardson MG. Postdischarge opioid use after cesarean delivery. Obstet Gynecol 2017; 130 (01) 36-41
    CrossrefPubMedGoogle Scholar
  • 19 Badreldin N, Grobman WA, Chang KT, Yee LM. Opioid prescribing patterns among postpartum women. Am J Obstet Gynecol 2018; 219 (01) 103.e1-103.e8
    CrossrefPubMedGoogle Scholar